Teva bupropion patent dispute
Executive Summary
Glaxo Wellcome files suit July 14 in Delaware district court charging Teva with violating a formulation patent for the antidepressant Wellbutrin. The patent in question, number 5,358,970, issued in October 1994, describes a method to prevent bupropion decomposition in instant-release tablets
Glaxo Wellcome files suit July 14 in Delaware district court charging Teva with violating a formulation patent for the antidepressant Wellbutrin. The patent in question, number 5,358,970, issued in October 1994, describes a method to prevent bupropion decomposition in instant-release tablets. |